Johnson & Johnson's $2 Billion Acquisition of Ambrx Signals Major Move in Cancer Treatment
TL;DR
Johnson & Johnson has made a $2 billion cash deal to acquire Ambrx Biopharma, joining other major pharmaceutical companies in a spree of acquisitions focused on antibody-drug conjugates in the oncology sector. This move comes as the industry anticipates increased spending to bolster pipelines ahead of looming patent expirations at the end of the decade.
Topics:businesshealthcare-and-pharmaceuticals#acquisitions#ambrx-biopharma#antibody-drug-conjugates#healthcare-and-pharmaceuticals#johnson-and-johnson#oncology
- J&J makes $2B push into ADCs with Ambrx buyout in oncology deal spree Endpoints News
- Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Business Wire
- J&J to Purchase Tumor-Antibody Biotech Ambrx for $2 Billion Bloomberg
- J&J to buy targeted cancer therapy developer Ambrx for $2 bln Reuters
- Ambrx Announces Sale to Johnson & Johnson GlobeNewswire
Want the full story? Read the original reporting
Read on Endpoints News